|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Japan Society of Gynecologic Oncology, .
Formulation Committee of the Treatment Guidelines for Cervical
Cancer, 2011. Kanehara & Co.; Tokyo: 2011, (In Japanese).
|
|
4
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer
Version II. 2013.
|
|
5
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eifel PJ, Winter K, Morris M, Levenback C,
Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic
irradiation with concurrent chemotherapy versus pelvic and
para-aortic irradiation for high-risk cervical cancer: An update of
radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol.
22:872–880. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R:
Balloon-occluded arterial infusion chemotherapy, simple total
hysterectomy and radiotherapy as a useful combination-therapy for
advanced cancer of the uterine cervix. Oncol Rep. 7:141–144.
2000.PubMed/NCBI
|
|
8
|
Souhami L, Gil RA, Allan SE, Canary PC,
Araújo CM, Pinto LH and Silveira TR: A randomized trial of
chemotherapy followed by pelvic radiation therapy in stage IIIB
carcinoma of the cervix. J Clin Oncol. 9:970–977. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tattersall MH, Lorvidhaya V, Vootiprux V,
Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A, Yen MS,
et al: Randomized trial of epirubicin and cisplatin chemotherapy
followed by pelvic radiation in locally advanced cervical cancer.
Cervical cancer study group of the asian oceanian clinical oncology
association. J Clin Oncol. 13:444–451. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Ogita S, Kaminou T, Nakamura K and Yamada R: Tumor marker and MR
imaging criteria for evaluating the efficacy of cyclic
balloon-occluded arterial infusion for advanced cancer of the
uterine cervix. Oncol Rep. 7:827–830. 2000.PubMed/NCBI
|
|
11
|
Ishiko O, Sumi T, Yoshida H, Ogita S and
Yamada R: Expression of apoptosis regulatory proteins in advanced
cancer of the uterine cervix after cyclic balloon-occluded arterial
infusion chemotherapy. Int J Oncol. 18:1151–1155. 2001.PubMed/NCBI
|
|
12
|
Okamoto E, Sumi T, Misugi F, Nobeyama H,
Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K and Ishiko O:
Expression of apoptosis-related proteins in advanced uterine
cervical cancer after balloon-occluded arterial infusion
chemotherapy as an indicator of the efficiency of this therapy. Int
J Mol Med. 15:41–47. 2005.PubMed/NCBI
|
|
13
|
Nobeyama H, Sumi T, Misugi F, Okamoto E,
Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K and Ishiko O:
Association of HPV infection with prognosis after neoadjuvant
chemotherapy in advanced uterine cervical cancer. Int J Mol Med.
14:101–105. 2004.PubMed/NCBI
|
|
14
|
Benedetti Panici P, Bellati F, Manci N,
Pernice M, Plotti F, Di Donato V, Calcagno M, Zullo MA, Muzii L and
Angioli R: Neoadjuvant chemotherapy followed by radical surgery in
patients affected by FIGO stage IVA cervical cancer. Ann Surg
Oncol. 14:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Köberle B, Grimaldi KA, Sunters A, Hartley
JA, Kelland LR and Masters JR: DNA repair capacity and cisplatin
sensitivity of human testis tumour cells. Int J Cancer. 70:551–555.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Riedl T, Hanaoka F and Egly JM: The
comings and goings of nucleotide excision repair factors on damaged
DNA. EMBO J. 22:5293–5303. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Z, Roginskaya M, Colis LC, Basu AK,
Shell SM, Liu Y, Musich PR, Harris CM, Harris TM and Zou Y:
Specific and efficient binding of xeroderma pigmentosum
complementation group A to double-strand/single-strand DNA
junctions with 3′- and/or 5′-ssDNA branches. Biochemistry.
45:15921–15930. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mer G, Bochkarev A, Gupta R, Bochkareva E,
Frappier L, Ingles CJ, Edwards AM and Chazin WJ: Structural basis
for the recognition of DNA repair proteins UNG2, XPA and RAD52 by
replication factor RPA. Cell. 103:449–456. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Batty DP and Wood RD: Damage recognition
in nucleotide excision repair of DNA. Gene. 241:193–204. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Liu Y, Yang Z, Utzat C, Wang G,
Basu AK and Zou Y: Cooperative interaction of human XPA stabilizes
and enhances specific binding of XPA to DNA damage. Biochemistry.
44:7361–7368. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guzder SN, Sommers CH, Prakash L and
Prakash S: Complex formation with damage recognition protein Rad14
is essential for Saccharomyces cerevisiae Rad1-Rad10 nuclease to
perform its function in nucleotide excision repair in vivo. Mol
Cell Biol. 26:1135–1141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shell SM and Zou Y: Other proteins
interacting with XP proteins. Adv Exp Med Biol. 637:103–112. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu X, Hu J, Han HY, Hua YJ, Zhou L, Shuai
WD, Du WY, Kuang CM, Chen S, Huang W and Liu RY: High expression of
XPA confers poor prognosis for nasopharyngeal carcinoma patients
treated with platinum-based chemoradiotherapy. Oncotarget.
6:28478–28490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsuji K, Yamada R, Kawabata M, Mitsuzane
K, Sato M, Iwahashi M, Kitayama S and Nakano R: Effect of balloon
occluded arterial infusion of anticancer drugs on the prognosis of
cervical cancer treated with radiation therapy. Int J Radiat Oncol
Biol Phys. 32:1337–1345. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
28
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ishida S, Lee J, Thiele DJ and Herskowitz
I: Uptake of the anticancer drug cisplatin mediated by the copper
transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA.
99:pp. 14298–14302. 2002; View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morimoto A, Serada S, Enomoto T, Kim A,
Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M,
et al: Annexin A4 induces platinum resistance in a chloride-and
calcium-dependent manner. Oncotarget. 5:7776–7787. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Q, Shi S, He W, Padilla MT, Zhang L,
Wang X, Zhang B and Lin Y: Retaining MKP1 expression and
attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance
through miR-940 inhibition. Oncotarget. 5:1304–1314. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu
X, Yang Y, Mo W, Huang W, Khoo SK, et al: Role of eIF3a in
regulating cisplatin sensitivity and in translational control of
nucleotide excision repair of nasopharyngeal carcinoma. Oncogene.
30:4814–4823. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mistry P, Kelland LR, Abel G, Sidhar S and
Harrap KR: The relationships between glutathione,
glutathione-S-transferase and cytotoxicity of platinum drugs and
melphalan in eight human ovarian carcinoma cell lines. Br J Cancer.
64:215–220. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu RY, Dong Z, Liu J, Zhou L, Huang W,
Khoo SK, Zhang Z, Petillo D, Teh BT, Qian CN and Zhang JT:
Overexpression of asparagine synthetase and matrix
metalloproteinase 19 confers cisplatin sensitivity in
nasopharyngeal carcinoma cells. Mol Cancer Ther. 12:2157–2166.
2013. View Article : Google Scholar : PubMed/NCBI
|
